PRME insider buying & filings

← All candidates

PRMEPrime Medicine, Inc.

NasdaqGM · Healthcare · $828.80M

$3.56

-3.78% · Sep 8

8 insider filings on record.
None of them an open-market buy in the last year.

Last Form 4 Aug 5 · scanned 1h ago

Price · 1Y · daily◆ 3 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$828.80M

Float

115.0M

64% public

Short % float

Pro

Price / profit

—

not yet profitable

Price / future profit

—

Price / sales

205.5

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

10% owner

Nelsen Robert

Bought $10.00M on Aug 1 — 3,030,300 sh @ $3.30, held indirect, 49% of their stake.

0 of 1 position beat the S&P

median +9.7% vs S&P +10.9% same spans

10% owner

ARCH Venture Partners XII, LLC

Bought $10.00M on Aug 1 — 3,030,300 sh @ $3.30, held indirect, 49% of their stake.

0 of 2 positions beat the S&P

median +9.7% vs S&P +10.9% same spans

10% owner

ARCH Venture Partners X, LLC

Bought $10.00M on Aug 1 — 3,030,300 sh @ $3.30, held indirect, 49% of their stake.

0 of 2 positions beat the S&P

median +9.7% vs S&P +10.9% same spans

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Aug 5BUYGv 2021 Gp, L.l.c.10% owner+46%indirect1,500,000 @ $3.30$4.95M

Aug 1BUYNelsen Robert10% owner+49%indirect3,030,300 @ $3.30$10.00M

Aug 1BUYARCH Venture Partners XII, LLC10% owner+49%indirect3,030,300 @ $3.30$10.00M

Aug 1BUYARCH Venture Partners X, LLC10% owner+49%indirect3,030,300 @ $3.30$10.00M

Jul 1BUYLiu David R.10% owner+0.1%direct21,000 @ $2.52$52.8K

3 more transactions on Pro →

Context

Wall St

$7.11 avg target

+99.8% vs today · 11 analysts · consensus Strong Buy

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

2 of 4 quarters beat

Q2 '26−$0.24 act+$0.02

Q1 '26−$0.28 act−$0.03

Q4 '25−$0.24 act+$0.02

Q3 '25−$0.32 act−$0.07

Coverage

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue EstimatesZacks · 08-06 Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks · 07-30 Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam TherapeuticsInsider Monkey · 07-15 PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing DrugStocktwits · 07-08

The file stays open

32 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Nelsen Robert

ARCH Venture Partners XII, LLC

ARCH Venture Partners X, LLC

32 filings on record.The next one will be too.

32 filings on record.
The next one will be too.